Hepatitis C treatments are an integral part of the biotech’s product line. Recent approval for a competitor’s comprehensive Hep C drug adds new pressure.
Looking for leads, investment insights, or competitive intelligence?
News about Gilead Sciences
The FDA approved Gilead's novel cancer-fighting gene therapy.
The price of the drug, which is to be administered just once to each patient, will be $373,000.
They're more popular than ever, even though the political winds are against them.
FDA approves Novartis treatment that reengineers human cells to kill cancer
Kite Pharma stock rose 29% on the news.